AIDS Research and Treatment / 2015 / Article / Tab 3

Research Article

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial

Table 3

HIV-1 RNA suppression <50 copies/mL over time, by HIV-1 subtype.

Darunavir/ritonavir
800/100 mg once daily
Darunavir/ritonavir
600/100 mg twice daily

HIV-1 subtype B

Week 414/64 (22%)14/78 (18%)
Week 833/64 (52%)32/78 (41%)
Week 1244/64 (69%)43/78 (55%)
Week 2448/64 (75%)55/78 (71%)
Week 3653/64 (83%)56/78 (72%)
Week 4853/64 (83%)56/78 (72%)

HIV-1 subtype non-B

Week 414/71 (20%)13/59 (22%)
Week 837/71 (52%)29/59 (49%)
Week 1247/71 (66%)39/59 (66%)
Week 2458/71 (82%)51/59 (86%)
Week 3658/71 (82%)53/59 (90%)
Week 4858/71 (82%)53/59 (90%)

All results shown are (%), unless otherwise stated.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.